Corona Remedies Ltd EPS

Corona Remedies Ltd EPS

Image

Corona Remedies Ltd

NSE: CORONA

EPS

₹ 30.17

Last updated on: Mar 02, 2026

Key Highlights

  • The Earning per Share of Corona Remedies Ltd is ₹ 30.17 as of 02 Mar 26 The earning per share of Corona Remedies Ltd changed from ₹ 4.9 to ₹ 6.75 over 7 quarters. This represents a CAGR of 20.09% .

Historical Earning per Share of Corona Remedies Ltd

No data available

* All values are in

Company Fundamentals for Corona Remedies Ltd

Market Cap

9,702 Cr

EPS

30.2

P/E Ratio (TTM)

52.4

P/B Ratio (TTM)

14.6

Day’s High

1594.9

Day’s Low

1580.0

DTE

0.1

ROE

26.5

52 Week High

1658.7

52 Week Low

1336.95

ROCE

33.3

Market Price of Corona Remedies Ltd

1M

1Y

3Y

5Y

Monitoring Corona Remedies Ltd share price can help you stay informed about potential market shifts and opportunities. *All values are in Rupees.

Last Ten Days Market Price

Date
leftPrice (₹)right
02 Mar 20261580.1
27 Feb 20261580.85
26 Feb 20261609.5
25 Feb 20261620.3
24 Feb 20261591.65
23 Feb 20261582.4
20 Feb 20261519.4
19 Feb 20261565.45
18 Feb 20261586.45
17 Feb 20261575.35

SWOT Analysis Of Corona Remedies Ltd

Strength

1

che

Weakness

1

che

Opportunity

0

che

Threats

0

che

BlinkX Score for Corona Remedies Ltd

Asset Value vs Market Value of Corona Remedies Ltd

Market Value

9,664

Asset Value

Value addition

25.7 X

362

* All values are in ₹ crores

Competitive Comparison of EPS

Company
leftMarket Capright
Corona Remedies Ltd9663
Sun Pharmaceutical Industries Ltd420531
Divis Laboratories Ltd169989
Torrent Pharmaceuticals Ltd147936
Cipla Ltd109200
Dr Reddys Laboratories Ltd108057

Historical Market Cap of Corona Remedies Ltd

No data available

* All values are in crore

Historical Revenue of Corona Remedies Ltd

No data available

* All values are in crore

Historical EBITDA of Corona Remedies Ltd

No data available

* All values are in crore

Historical Net Profit of Corona Remedies Ltd

No data available

* All values are in crore

Dividend Payout Over Time

No data available

Corona Remedies Ltd News Hub

Shares of Corona Remedies list in B group

The equity shares of Corona Remedies (Scrip Code: 544644) are listed effective 15 December 2025 and

Read more

15 Dec 25

Corona Remedies Q2 PAT climbs 22% YoY to Rs 52 cr

Profit before tax (PBT) increased 21.67% year on year (YoY) to Rs 69.78 crore in Q2 FY26. Earnings B

Read more

03 Jan 26

Corona Remedies gains as Q2 PAT climbs 22% YoY to Rs 52 cr

Profit before tax (PBT) increased 21.67% year on year (YoY) to Rs 69.78 crore in Q2 FY26. Earnings B

Read more

05 Jan 26

Corona Remedies spurts on market debut

The stock was listed at Rs 1,452, exhibiting a premium of 36.72% to the issue price. So far, the sto

Read more

15 Dec 25

Document

Annual Reports

N/A

dropdown
download

Credit Ratings

N/A

dropdown
download

Concalls

Data not available

FAQs for EPS of Corona Remedies Ltd

What is the EPS of Corona Remedies Ltd stock?

The Earnings Per Share (EPS) of Corona Remedies Ltd is 30.17. An EPS is the amount of net income attributed to each share of a common stock.

How is Corona Remedies Ltd EPS calculated?

The EPS of Corona Remedies Ltd is calculated by dividing the net income by the number of outstanding shares. The formula is EPS = (Net Income - Dividends on Preferred Stock) / Average Outstanding Shares.

How often does Corona Remedies Ltd report its EPS?

Corona Remedies Ltd typically reports its EPS quarterly and annually, in conjunction with its financial statements and earnings reports.

What factors can influence Corona Remedies Ltd EPS?

Factors that influence the EPS of Corona Remedies Ltd include revenue changes, cost fluctuations, operational efficiency, tax rates, and one-time gains or losses.

Can Corona Remedies Ltd EPS growth indicate future performance?

Yes, consistent growth in Corona Remedies Ltd EPS can suggest strong financial health and effective management, potentially indicating positive future performance.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions